Tixagevimab

Names

[ CAS No. ]:
2420564-02-7

[ Name ]:
Tixagevimab

Biological Activity

[Description]:

Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor[1].

[Related Catalog]:

Research Areas >> Infection
Signaling Pathways >> Anti-infection >> SARS-CoV

[In Vivo]

Tixagevimab 可以与 Cilgavimab 组合，形成 AZD7442，AZD7442（2，4 或 16 mg/kg，静脉注射）在感染 G61 菌株的仓鼠以及在感染了 Omicron 变种的仓鼠中，可以导致肺部感染滴度和病毒 RNA 水平呈剂量依赖性下降，且与 2 mg/kg 剂量的动物相比，16 mg/kg 剂量的感染滴度显著降低[2]。

[References]

[1]. Jinhui Dong, et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat Microbiol. 2021 Oct;6(10):1233-1244.  

[2]. Jean-Sélim DRIOUICH, et al. Activity of Tixagevimab/Cilgavimab against the Omicron variant of SARS-CoV-2 in a hamster model.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.